DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20210049

Role of danazol in management of mastalgia: a tertiary care experience from North India

Natasha Thakur, Nayeem Ul Hassan, Yaqoob Hassan, Mohd. Yousuf Dar, Gowher Aziz, Syed Muzamil Ishfaq Andrabi, Sheikh Mudashir Khurshid, Javed Ahmad Bhat

Abstract


Background: Mastalgia is one of the most common complains, for which women consult their general practitioner. Majority of the patients presented with fear of cancer so patient education and availability of quality radiological and pathological services are crucial in the management of patients with mastalgia. This study is aimed to assess the efficacy of danazol on cyclical and non-cyclical mastalgia.

Methods: The study was conducted at Sher-I-Kashmir institute of medical sciences (SKIMS), Srinagar between January 2018 to July 2019. All the patients with mastalgia between 19 to 45 years presenting to surgical OPD were considered eligible for the study. After standard triple assessment, all our patients received 100 mg of danazol twice a day for a period of 3 months. Data was collected and analyzed.

Results: All the patients with mastalgia between 19 to 45 years presenting to surgical OPD were considered eligible for the study. 72% of our patients presented with cyclic mastalgias while as 28% had non cyclic symptoms. 89.65% of patients in cyclic group had responded to cap. Danazol 100 mg twice daily and 81.81% had shown improvement in non-cyclic group. 19 of our patients had side effects due to medications.14 of our patients developed recurrence after discontinuation of medication.

Conclusions: Danazol is very effective in the management of both cyclical and non-cyclical mastalgias. However, cost of the drug and side effects limits its use. Further studies are needed to examine the long-term effectiveness and sustainability of the effects after stopping the treatment.


Keywords


Breast pain, Cyclic, Non-cyclic, Danazol, Mastalgia

Full Text:

PDF

References


Cooper S. Illustrations of the Diseases of the Breast: Pt. 1, Part 1, London: Longman, Rees, Orme, Brown, and Green- Breast. Medical Heritage Library. 1829: 108.

Alvero R, Ferri FF, Fort GG. Fibrocystic breast disease. In: Ferri FF, edFerri’s Clinical Advisor 2015. 1st ed. Philadelphia, PA: Elsiever Mosby. 2015: 457.

Olawaiye A, Withiam-Leitch M, Danakas G, Kahn K. Mestalgia: a review of management. J Reprord med. 2005;50(12):923-39.

Kataria K, Dhar A, Srivastava A, Kumar S, Goyal A. A Systematic Review of Current Understanding and Management of Mastalgia. Indian J Surg. 2014;76(3):217-22.

BeLieu RM. Mastodynia. Obstet Gynecol clin North Am. 1994;21(3):461-77.

Hughes LE, Mansel RE, Webester DJT. Aberrations of normal development and involution (ANDI): A new perspective on pathogenesis and nomenclature of benign breast disorders. Lancet. 1987;2:1316-9.

Chang G, Song E, Jia W, Qin L, Guo J, Jia H et al. A double blind randomized controlled trial of toremifen therapy for mastalgia. Arch Surg. 2006;141(1):43-7.

Mansel RE, Goyal A, Preece P, Linster S, Maddox PR, Gateley C et al. European randomized multi centric study of gosserlin in the management of mastalgia. Am. J obst gynecol. 2004;191(6):1942-9.

Greenblatt RB, Dmowski WP, Maheslh VB, Scholer HFL. Clinical studies with an an-tigonadotroplin-danazol. Fertil Stetil. 1971;22:102-12.

Asch RH, Grecnblatt RB. The use of an impeded androgen-danazolin the managemcnt of benign breast disordcrs. Ami Y Obstet Gynlecol. 1977;127:130-4.

Nezhat C, Asch RH, Greenblatt RB. Danazol for benign breast disease. Am J Obstet Gynecol. 1980;137(5):604-7.

Gateley CA, Maddox PR, Pritchard GA, Sheradan W, Harrison BJ, Pye JK et al. Plasma fatty acid profile in benign breast disorders. Br J Surg. 1992;79(5):477-99.

Parveen S, Sarwar G, Ali M, Channa GA. Danazol versus oil of evening primrose in the treatment of mastalgia. Pak J Surg. 2007;23(1):10-3.

Doberl A, Tobiassen T, Rasmussen T. Treatment of recurrent cyclical mastodynia in patients with fibrocystic breast disease. A double blind randomized controlled study. Gynaecol Scant Suppt. 1984;123:177-84.

Asch RH, Greenblott RB. The use of an impeded androgen denazol in the management of benign breast disorders. Amj Obstet Gynecol. 1977;127(2):130-4.

Hinton CP, Bishop HN, Holliday HW, Doyle PJ, Blamey RW. A double-blind controlled trial of danazol and bromocriptine in the management of severe cyclical brest pain. Br J Clin Pract. 1986;40:326-30.

Dhar A, Srivastava A. Role of centchroman in regression of mastalgia and fibro adenoma. World J surg. 2007;31:1180-6.

Adhikary OD, Jyoti DM, Sarkar A. Comparison of effectiveness among centchroman, Danzol and evening primrose oil for the management of mastalgiain benign breast diseases. J dental medi sci. 2018;17(7):1-5.